First test: how kidneys handle new Weight-Loss pill
NCT ID NCT07347808
Summary
This early study tested how a single dose of an experimental obesity medication called VCT220 is processed by the body in people with moderate kidney problems compared to people with normal kidney function. Sixteen participants received one pill, and researchers measured drug levels in their blood for three days to understand how kidney health affects the drug. The goal is to gather data to help determine safe future dosing for people with kidney issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Conditions
Explore the condition pages connected to this study.